KEGG   DRUG: Avutometinib and defactinib
Entry
D13120            Mixture   Drug                                   
Name
Avutometinib and defactinib;
Avmapki fakzynja (TN)
Component
(Avutometinib [DR:D12515] | Avutometinib potassium [DR:D12534]), (Defactinib [DR:D10618] | Defactinib hydrochloride [DR:D10619])
Class
Metabolizing enzyme substrate
 DG01642  CYP2C9 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Efficacy
Antineoplastic
  Disease
Serous ovarian cancer (KRAS-mutated) [DS:H00027]
Comment
Avutometinib is metabolized by CYP3A4.
Defactinib is metabolized by CYP3A4 and CYP2C9.
Metabolism
Enzyme: CYP3A4 [HSA:1576], CYP2C9 [HSA:1559]
Interaction
Brite
Drug groups [BR:br08330]
 Metabolizing enzyme substrate
  DG01642  CYP2C9 substrate
   D13120  Avutometinib and defactinib
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D13120  Avutometinib and defactinib
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D13120
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D13120
Other DBs
PubChem: 513131724
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system